Log In
Print
BCIQ
Print
Print this Print this
 

MGD007

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionBispecific antibody developed using MacroGenics' DART technology that is designed to redirect T cells to target glycoprotein A33 transmembrane (GPA33; A33)-expressing colorectal cancer cells
Molecular Target Glycoprotein A33 transmembrane (GPA33) (A33)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationColorectal cancer
Indication DetailsTreat colorectal cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today